David L Chan COSA 2015 ASM

Abstracts this author is presenting:

• Symptom burden of Australia and New Zealand (ANZ) patients with Neuroendocrine Tumours (NET)  — Posters 2
• A retrospective study of dual ¹⁸F-fluorodeoxyglucose/⁶⁸Gallium DOTATATE (FDG/⁶⁸Ga-DOTATATE) positron emission tomography (PET) grading and its prognostic value in metastatic pancreatic neuroendocrine tumours (PNET) — Posters 2
• Experience of Australia and New Zealand (ANZ) patients with neuroendocrine tumours (NET) treated at a NET specialist centre: Results of a national survey and the Royal North Shore experience — Posters 2